Country for PR: United Kingdom
Contributor: PR Newswire Europe
Wednesday, November 25 2020 - 09:00
RedHill Biopharma to Present at Evercore ISI HealthCONx and Piper Sandler Healthcare Conferences
TEL AVIV, Israel and RALEIGH, N.C., Nov. 25, 2020 /PRNewswire-AsiaNet/ --

RedHill Biopharma Ltd. ( ) (Nasdaq: RDHL) 
("RedHill" or the "Company"), a specialty biopharmaceutical company, today 
announced that it will present and participate at the following virtual 
conferences in December:

Logo -

Evercore ISI 3rd Annual HealthCONx Conference 
Fireside chat and an open Q&A: Thursday, December 3, 2020, 8 a.m. EST
Moderator: Umer Raffat, Equity Research – Biotech-large, Pharma-major, 
Specialty Pharma
Speaker: Dror Ben-Asher, CEO & Gilead Raday, Chief Operating Officer

Piper Sandler 32nd Annual Virtual Healthcare Conference 
Fireside chat: Available on-demand from November 23, 2020
Moderator: David Amsellem, Managing Director, Sr. Research Analyst, Specialty 
Speaker: Guy Goldberg, Chief Business Officer 

The webcasts will be available for replay for 30 days on the Company's website:

About RedHill Biopharma     

RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company 
primarily focused on gastrointestinal and infectious diseases. RedHill promotes 
the gastrointestinal drugs, Movantik(R) for opioid-induced constipation in 
adults with non-cancer pain[1], Talicia(R) for the treatment of Helicobacter 
pylori (H. pylori) infection in adults[2], and Aemcolo(R) for the treatment of 
travelers' diarrhea in adults[3]. RedHill's key clinical late-stage 
investigational development programs include: (i) RHB-204, with an ongoing 
Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) disease; (ii) 
opaganib (Yeliva(R)), a first-in-class SK2 selective inhibitor targeting 
multiple indications with a Phase 2/3 program for COVID-19 and Phase 2 studies 
for prostate cancer and cholangiocarcinoma ongoing; (iii) RHB-104, with 
positive results from a first Phase 3 study for Crohn's disease; (iv) RHB-102 
(Bekinda(R)), with positive results from a Phase 3 study for acute 
gastroenteritis and gastritis and positive results from a Phase 2 study for 
IBS-D; (v) RHB-107 (upamostat), a Phase 2-stage first-in-class, serine protease 
inhibitor, targeting cancer and inflammatory gastrointestinal diseases and is 
also being evaluated for COVID-19 and (vi) RHB-106, an encapsulated bowel 
preparation. More information about the Company is available at 

This press release contains "forward-looking statements" within the meaning of 
the Private Securities Litigation Reform Act of 1995. Such statements may be 
preceded by the words "intends," "may," "will," "plans," "expects," 
"anticipates," "projects," "predicts," "estimates," "aims," "believes," 
"hopes," "potential" or similar words. Forward-looking statements are based on 
certain assumptions and are subject to various known and unknown risks and 
uncertainties, many of which are beyond the Company's control and cannot be 
predicted or quantified, and consequently, actual results may differ materially 
from those expressed or implied by such forward-looking statements. Such risks 
and uncertainties include risks and uncertainties associated with (i) the 
initiation, timing, progress and results of the Company's research, 
manufacturing, preclinical studies, clinical trials, and other therapeutic 
candidate development efforts, and the timing of the commercial launch of its 
commercial products and ones it may acquire or develop in the future; (ii) the 
Company's ability to advance its therapeutic candidates into clinical trials or 
to successfully complete its preclinical studies or clinical trials (iii) the 
extent and number and type of additional studies that the Company may be 
required to conduct and the Company's receipt of regulatory approvals for its 
therapeutic candidates, and the timing of other regulatory filings, approvals 
and feedback; (iv) the manufacturing, clinical development, commercialization, 
and market acceptance of the Company's therapeutic candidates and Talicia(R); 
(v) the Company's ability to successfully commercialize and promote 
Movantik(R), Talicia(R) and Aemcolo(R); (vi) the Company's ability to establish 
and maintain corporate collaborations; (vii) the Company's ability to acquire 
products approved for marketing in the U.S. that achieve commercial success and 
build and sustain its own marketing and commercialization capabilities; (viii) 
the interpretation of the properties and characteristics of the Company's 
therapeutic candidates and the results obtained with its therapeutic candidates 
in research, preclinical studies or clinical trials; (ix) the implementation of 
the Company's business model, strategic plans for its business and therapeutic 
candidates; (x) the scope of protection the Company is able to establish and 
maintain for intellectual property rights covering its therapeutic candidates 
and commercial products and its ability to operate its business without 
infringing the intellectual property rights of others; (xi) parties from whom 
the Company licenses its intellectual property defaulting in their obligations 
to the Company; (xii) estimates of the Company's expenses, future revenues, 
capital requirements and needs for additional financing; (xiii) the effect of 
patients suffering adverse events using investigative drugs under the Company's 
Expanded Access Program; and (xiv) competition from other companies and 
technologies within the Company's industry. More detailed information about the 
Company and the risk factors that may affect the realization of forward-looking 
statements is set forth in the Company's filings with the Securities and 
Exchange Commission (SEC), including the Company's Annual Report on Form 20-F 
filed with the SEC on March 4, 2020. All forward-looking statements included in 
this press release are made only as of the date of this press release. The 
Company assumes no obligation to update any written or oral forward-looking 
statement, whether as a result of new information, future events or otherwise 
unless required by law.
Company contact:                            Media contact (U.S.):
Adi Frish                                   Bryan Gibbs
Chief Corporate &                           Vice President
Business Development Officer                Finn Partners
RedHill Biopharma                           +1 212 529 2236


[1] Full prescribing information for Movantik(R) (naloxegol) is available at:   

[2] Full prescribing information for Talicia(R) (omeprazole magnesium, 
amoxicillin and rifabutin) is available at:       

[3] Full prescribing information for Aemcolo(R) (rifamycin) is available at:

SOURCE:  RedHill Biopharma Ltd.